Bullish (BLSH) Soars Anew on Strong Buying
Cryptocurrency exchange Bullish saw its share prices grow by 9.75 percent on Thursday to close at $74.63 apiece as investors continued to post strong confidence in the company.
After its debut on the stock market on Wednesday, August 13, shares of Bullish (NYSE:BLSH) already rose by a whopping 219 percent from its $37 IPO price, to an intra-day high of $118, before paring gains to finish lower.
PTstock/Shutterstock.com
The company successfully raised $1.1 billion in fresh funds from its IPO, covering 30 million shares or 19.9 percent of its total stock. As of Thursday, it was valued at nearly $11 billion.
Bullish (NYSE:BLSH) joins the roster of publicly listed cryptocurrency exchange platforms, taking advantage of President Donald Trump's favorable attitude towards the cryptocurrency industry.
Unlike most crypto exchanges, Bullish (NYSE:BLSH) primarily caters to institutional clients, offering spot trading, margin trading, and crypto derivatives, targeting the stable and recurring revenue stream that institutional investors provide.
While we acknowledge the potential of BLSH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Analyst Estimates: Here's What Brokers Think Of Springer Nature AG & Co. KGaA (ETR:SPG) After Its Second-Quarter Report
It's been a pretty great week for Springer Nature AG & Co. KGaA (ETR:SPG) shareholders, with its shares surging 17% to €22.65 in the week since its latest second-quarter results. Results were roughly in line with estimates, with revenues of €476m and statutory earnings per share of €0.35. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the most recent consensus for Springer Nature KGaA from six analysts is for revenues of €1.92b in 2025. If met, it would imply an okay 2.4% increase on its revenue over the past 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.91b and earnings per share (EPS) of €1.30 in 2025. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results. See our latest analysis for Springer Nature KGaA There's been no real change to the consensus price target of €28.01, with Springer Nature KGaA seemingly executing in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Springer Nature KGaA analyst has a price target of €31.20 per share, while the most pessimistic values it at €24.85. This is a very narrow spread of estimates, implying either that Springer Nature KGaA is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Springer Nature KGaA's growth to accelerate, with the forecast 4.9% annualised growth to the end of 2025 ranking favourably alongside historical growth of 1.4% per annum over the past year. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 4.4% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Springer Nature KGaA is expected to grow at about the same rate as the wider industry. The Bottom Line The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. At least one of Springer Nature KGaA's six analysts has provided estimates out to 2027, which can be seen for free on our platform here. You should always think about risks though. Case in point, we've spotted 1 warning sign for Springer Nature KGaA you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Android Authority
9 minutes ago
- Android Authority
Kindle might have another competitor headed to shelves
C. Scott Brown / Android Authority TL;DR an online bookstore, was launched in January 2020 to help independent bookstores survive Amazon. Now the company may be introducing its first physical e-reader, presenting a direct competitor to the Amazon Kindle. There is currently a blank landing page for an e-reader visible on the site. In a compelling new development for e-book readers, known for championing independent bookstores, might soon bring a fresh competitor to the hardware space dominated by Amazon's Kindle. Since its launch in 2020, has carved out a niche as the Amazon alternative for people who want their online purchases to support small, local shops. Over the past five years, the platform has funneled millions of dollars to independent bookstores, cementing itself as a functional, reader-friendly marketplace. Don't want to miss the best from Android Authority? Set us as a preferred source in Google Search to support us and make sure you never miss our latest exclusive reports, expert analysis, and much more. In early 2025, the company turned a new page by launching its own e-book store and reading app. The app offers an extensive catalog, from bestsellers to niche titles, and lets buyers choose which indie shop gets a cut of their purchase. Right now, digital reading experience lives entirely in software. But that could change. CEO Andy Hunter has openly floated the idea of a dedicated e-reader, possibly launched via crowdfunding to keep the project aligned with the company's community-driven ethos. As spotted by GoodEReader, the site now features a landing page for the potential hardware. The presumed vision for this hardware isn't a walled garden like Kindle, but something more open to multiple formats. Think along the lines of Kobo or Boox devices, but with the clear identity baked in. For readers, that could mean breaking free from the 'one-store, one-device' model and choosing an ecosystem that better fits their values. For indie bookstores, it could be a tangible product to sell alongside print titles and a way to reach tech-savvy readers they might otherwise miss. For the e-reader industry as a whole, it could be another voice in the ongoing conversation about digital rights, open formats, and fair revenue sharing. For now, this is mostly rumors, but if hints turn into hardware, a e-reader could be an intriguing shake-up of the e-reader space. Follow
Forbes
10 minutes ago
- Forbes
Apple iOS 18.6.1 Surprise iPhone Software: Should You Upgrade?
If you'd thought that we'd seen the last of iOS 18 with the recent release of iOS 18.6, you wouldn't have been alone. But Apple has released a new update that specifically brings back a missing feature to millions of Apple Watches. This post has the initial thoughts on the new release and I'll be updating this post over the coming week and will make a final assessment on Friday, Aug. 8. Who Is It For And How Do You Get It? Apple iOS 18.6.1 is compatible with all iPhones from 2018 on. That's the iPhone XS, iPhone XS Plus and iPhone XR models and every phone since. That means the iPhone 11 series, iPhone 12, iPhone 13 and so on right up to the iPhone 16 series, plus the second- and third-generation iPhone SE models as well as the iPhone 16e. If you have any of these phones except the first three, iPhone XS, iPhone XS Plus and iPhone XR, they will work with iOS 26. To update, find the iPhone's Settings app, click on General, then Software Update. Then, choose Download and Install, and the software will download from there. This is a medium download, around 720MB, but it should be reasonably quick to install. What It's About This update, though is recommended for all users, is specifically to introduce a benefit for millions of Apple Watch users. A patent dispute between Apple and medical equipment company Masimo led to the blood oxygen monitoring feature on U.S.-sold Apple Watch Series 9 and Apple Watch Ultra 2 to be disabled. It never appeared on Apple Watch Series 10 models sold in the States. The software update means all compatible Apple Watches sold anywhere to have the feature again, once this update and a watchOS 11.6.1 update are installed. It's essentially a workaround: you still activate the Blood Oxygen app on your Apple Watch, but it now transmits data to the iPhone where it is calculated and analyzed, with the result found in the Health app under the Respiratory section. Compatible Apple Watches comprise Series 7, Series 8, Series 9, Apple Watch Ultra and Apple Watch Ultra 2. You can read more about the blood oxygen feature's return here. Apple iOS 18.6.1 Security No, there are no security features in this update, Apple says. Mind you, there were more than 20 in the last one, and that was scarcely more than two weeks ago, so perhaps that's no surprise. Initial Reactions Some users have reported a snappier performance on their iPhones though nobody has said it introduced new problems, I believe. One Redditor said their iPad now had a blank screen, but to be clear there hasn't been an iPad update. Apple iOS 18.6.1 Initial Verdict: Update If you are in the U.S. and have an Apple Watch or are going to get one in the future, this is a no-brainer. For the rest of us, go ahead, there's no harm here and maybe you'll find a snappier iPhone as a result. If you have an Apple Watch, don't forget to install watchOS 11.6.1 as well. Final verdict next week.
